Choroidal Neovascularization - A Pipeline Analysis Report

Overview of the drug development pipeline for choroidal neovascularization

It has been observed that choroidal neovascularization is the creation of new blood vessels in the choroid layer of the eye. It is a common cause of neovascular degenerative maculopathy, which is also known as wet macular degeneration. It is commonly exacerbated by extreme myopia, malignant myopic degeneration, or age-related developments. The common symptoms of choroidal neovascularization are sudden deterioration of central vision, color disturbances, blank spots in the vision and painless vision loss, feeling of pressure behind the eye, and distorted vision.

The diagnosis of choroidal neovascularization is done using a type of perimetry called preferential hyperacuity perimetry. Based on fluorescein angiography, the choroidal neovascularization may be described as classic or occult. Two other tests that help identify choroidal neovascularization include indocyanine green angiography and optical coherence tomography. The most efficient approach for the treatment of choroidal neovascularization is monotherapy.

According to this pipeline analysis report, all the drug molecules in the pipeline are being developed for the treatment of choroidal neovascularization. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Pipeline analysis report on drug development for choroidal neovascularization: Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of choroidal neovascularization. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are

• F. Hoffmann-La Roche
• Formycon
• Graybug Vision
• Iconic Therapeutics
• Isarna Therapeutics

Therapeutic assessment of the drug development pipeline for choroidal neovascularization by route of administration

• Intravitreal

The intravitreal route of administration (ROA) involves the administration of the drug directly into the eye with a syringe, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for choroidal neovascularization by therapy

• Monotherapy
• Monotherapy / Combination Therapy

According to this pipeline analysis report, most of the molecules that are currently in the drug pipeline for choroidal neovascularization are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for choroidal neovascularization?
• What are the companies that are currently involved in the development of drug molecules for choroidal neovascularization?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.